NCT00790647View on ClinicalTrials.gov

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

November 30, 2014

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

filgrastim

16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection

DRUG

bortezomib

1.0 mg/m2/dose D -6, D-3, D +1, D + 4

DRUG

melphalan

100 mg/m2/dose D -2, D -1

PROCEDURE

Stem Cell Infusion

infusion of previously collected autologous stem cells

Trial Locations (1)

02118

Boston University Cancer Research Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Medical Center

OTHER